PinkDx, Inc.
Giulia Kennedy currently serves as a Board Member at Encodia and Acuamark Diagnostics, Inc., and is the Co-Founder and Chief Scientific Officer of PinkDx, Inc. With extensive experience in the biomedical field, Kennedy has held significant positions, including Chief Scientific Officer and Chief Medical Officer at Veracyte, Inc., where contributions included leading R&D teams to generate substantial revenue and developing commercial diagnostic products. Kennedy's background also includes roles at Affymetrix, Chiron Corporation, and Millennium Pharmaceuticals, focusing on cancer gene discovery, assay development, and genetic mapping for diabetes research. Academically, Kennedy completed a Postdoctoral Fellowship in Genome Sciences at the University of California, San Francisco, and earned a Ph.D. in Biochemistry from Case Western Reserve University School of Medicine.
This person is not in any teams
PinkDx, Inc.
PinkDx is an early-stage women’s Healthcare company dedicated to building a leading enterprise bringing equitable care to women. Initially, the company is focused on the discovery and development of novel, new approaches to improve the journey millions of women navigate in getting answers to symptoms that are suspicious for cancer. PinkDx tests will improve patient outcomes, provide answers for physicians, and reduce the time and cost of care. The PinkDx co-founders are industry veterans with a passion for building a women’s health enterprise and for the opportunity to have impact for women all over the world. The Company has raised a $40 million Series A from top investors.